No Data
No Data
Hang Seng Index: Benefiting from policy support, biotechnology stocks have seen three consecutive months of inflows.
The Hang Seng Index company stated that there are signs of improvement in the recent situation of biotechnology stocks, as well as benefitting from policy support and three consecutive months of inflow of funds.
Express News | First Patient Enrolled in the US Phase 2 Combination Therapy of Akeso's Ligufalimab With Azacitidine for Myelodysplastic Syndrome
Hong Kong stocks unusual | Akeso (09926) rose more than 3%. The first patient with MDS treated with AK117 combination therapy was enrolled in the international multicenter Phase II clinical trial.
Akeso (09926) rose more than 3%, as of press time, the increase was 3.35%, with a price of HK$43.15 and a turnover of HK$31.4993 million.
Akeso (09926) rose nearly 3% in the morning amid Hong Kong stock market volatility. Institutions are bullish about the huge potential of Yivocide in first-line NSCLC treatment.
Akeso (09926) rose nearly 3% in the morning. As of press time, it has risen by 2.26% and is trading at HKD 42.95, with a turnover of HKD 72.7033 million.
Innovative drug concept rises against the market, with Innovent Bio (01801) increasing by 3.85%. The State Drug Administration has agreed to carry out related evaluation and approval pilots in Beijing and Shanghai.
Jingu Wealth News | Innovative drug concept rises against the trend, with Remegen (09995) up 6.15%, Innovent Bio (01801) up 3.85%, Akeso (09926) up 2.84%, Hutchmed (China) (00013) up 2.55%, Frontage (01521) up 2.41%, Innocare (09969) up 1.96%, Canbridge Life Sciences-B (02162) up 1.86%, and BeiGene (06160) up 1.21%. The National Medical Products Administration has approved the pilot program for optimizing clinical trial evaluation and approval of innovative drugs in Beijing and Shanghai after review.
Hong Kong stock concept tracking | National Medical Products Administration approved the pilot program of optimizing the clinical trial review and approval of innovative drugs in Peking and Shanghai, and innovative drugs are expected to outperform other s
The pharmaceutical industry is expected to see overall year-on-year improvement and quarter-on-quarter growth in performance in the second half of the year.
No Data
MayFlower : It was predictable..
Midnite52 : yep